Navigation

Idiopathic pulmonary fibrosis - pirfenidone [ID334]

Pirfenidone for treating idiopathic pulmonary fibrosis

Status: History
Expected date of issue: April 2013
Referral date: June 2010
Process: STA
Notes:

Scoped within Batch 10

Topic area:
 

NICE project team

Executive Lead: Gillian Leng
Technical Lead: Linda Landells
Communications manager: Paul Cooney
Project manager: Kate Moore
Top


 

Provisional schedule

Closing date for invited submissions / evidence submission: 1 December 2011
1st appraisal committee meeting: 24 October 2012
2nd appraisal committee meeting 29 January 2013
Top


 

Consultees and commentators

Consultees Commentators (no right to submit or appeal)

Manufacturers/sponsors

  • Intermune (pirfenidone)

Patient/carer groups

  • British Lung Foundation
  • South Asian Health Foundation

Professional groups

  • Association for Respiratory Technology and Physiology
  • British Thoracic Society
  • Royal College of Nursing
  • Royal College of Pathologists
  • Royal College of Physicians

Others

  • Berkshire East Teaching PCT
  • Department of Health
  • Welsh Government

General

  • Commissioning Support Appraisals Service
  • Department of Health, Social Services and Public Safety for Northern Ireland
  • HealthCare Improvement Scotland

Comparator manufacturers

  • AAH Pharmaceuticals (azathioprine, prednisolone)
    (confidentiality agreement not signed, not participating)
  • Actavis UK (azathioprine prednisolone)
    (confidentiality agreement not signed, not participating)
  • Alliance Pharmaceuticals (prednisolone)(confidentiality agreement not signed, not participating)
  • Almus Pharmaceuticals (azathioprine prednisolone)
    (confidentiality agreement not signed, not participating)
  • Arrow Generics (azathioprine)
    (confidentiality agreement not signed, not participating)
  • Aspen (azathioprine)
    (confidentiality agreement not signed, not participating)
  • Co-Pharma Ltd (prednisolone)
    (confidentiality agreement not signed, not participating)
  • Focus Pharmaceuticals (azathioprine)(confidentiality agreement not signed, not participating)
  • LPC Medical UK (prednisolone)(confidentiality agreement not signed, not participating)
  • Martindale Pharmaceuticals (N-acetylcysteine)
    (confidentiality agreement not signed, not participating)
  • Metwest Pharmaceuticals (prednisolone)(confidentiality agreement not signed, not participating)
  • Mylan (azathioprine)
    (confidentiality agreement not signed, not participating)
  • Sandoz Ltd (azathioprine)
    (confidentiality agreement not signed, not participating)
  • Tillomed Laboratories (azathioprine)(confidentiality agreement not signed, not participating)
  • Teva UK (prednisolone, N-acetylcysteine)(confidentiality agreement not signed, not participating)
  • Winthrop Pharmaceuticals UK (prednisolone)
    (confidentiality agreement not signed, not participating)
  • Wockhardt Uk (prednisolone)
    (confidentiality agreement not signed, not participating)

Relevant research groups

  • MRC Clinical Trials Unit

Evidence Review Group

  • Southampton Health Technology Assessment Centre (SHTAC), University of Southampton
  • National Institute for Health Research Health Technology Assessment Programme

Associated guideline groups

  • National Clinical Guidelines Centre

Associated public health groups

  • None

Top


 

Project history

Date Update

26 April 2012

 

The Appraisal Committee was due to meet on 14th May 2012 to discuss the use of pirfenidone for the treatment of idiopathic pulmonary fibrosis.

Following discussions with the manufacturer of pirfenidone we have concluded that we will not be in a position to release all the information necessary for a full consultation on the provisional guidance and evaluation report following the committee meeting.

In light of this, we have decided to reschedule this appraisal. Consequently the discussion of this appraisal at the committee meeting on the 14th May 2012 has been cancelled.

6 January 2012

 

Following on from information received from the manufacturer, this appraisal has been rescheduled.

The first Appraisal Committee Meeting will take place on 14th May 2012. The second meeting if required will be on 18th July 2012.

1 February 2011

 

Please note that following information received, NICE has decided to reschedule this appraisal. We now anticipate that the appraisal will begin during early October 2011. The deadline for submissions is expected in approximately early December 2011.

Top


 

Key documents

This page was last updated: 22 April 2013

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.

Selected, reliable information for health and social care in one place

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.